SML3161

GSK2126458

≥98% (HPLC)

• 同義詞: 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, GSK 2126458, GSK 458, GSK-2126458, GSK-458, GSK2126458A, GSK458, Omipalisib
• 經驗公式（希爾表示法）: C₂₅H₁₇F₂N₅O₃S
• CAS號碼: 1086062-66-9
• 分子量：: 505.50
• MDL號碼: MFCD16038929
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear
• 儲存溫度: 2-8°C
• SMILES 字串: FC(C=C1F)=CC=C1S(NC2=CC(C3=CC4=C(C5=CN=NC=C5)C=CN=C4C=C3)=CN=C2OC)(=O)=O
• InChI: 1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3
• InChI 密鑰: CGBJSGAELGCMKE-UHFFFAOYSA-N

描述

生化／生理作用

GSK2126458 (GSK458) is an orally active, highly potent and selective ATP site inhibitor against phosphoinositide 3-kinase (PI3K p110α CI50 = 40 pM; p100 α/δ/γ/β Ki = 19/24/60/130 pM; p110α E542K/E545K/H1047R Ki = 8/8/9 pM), mTOR (mTORC1/C2 Ki = 180/300 pM) and DNA-PK (IC50 = 280 pM) with >10,000-fold selectivity over more than 240 other kinases evaluated. GSK458 inhibits cellular AKT pS473 and growth of breast cancer cells in cultures (pAKT/growth IC50 = 0.41/3 nM/T-47D and 0.18/2.4/BT-474) and in vivo (0.3-3 mg/kg, 5x per wk for 3 wks p.o. in mice).

Orally active, highly potent and selective ATP site phosphoinositide 3-kinase inhibitor against PI3K p110 α/δ/γ/β, mTOR and DNA-PK in vitro and in vivo.

安全資訊

• 象形圖: GHS08,GHS07
• 訊號詞: Danger
• 危險聲明: H302,H361fd,H372
• 防範說明: P202 - P260 - P264 - P270 - P301 + P312 - P308 + P313
• 危險分類: Acute Tox. 4 Oral - Repr. 2 - STOT RE 1
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable